Stock Fundamentals

Company Information

Company Name
Revolution Medicines Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US76155X1000
CIK: 0001628171
CUSIP: 76155X100
Currency: USD
Full Time Employees: 883
Phone: 650 481 6801
Fiscal Year End: December
IPO Date: Feb 13, 2020
Description:

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Address:

700 Saginaw Drive, Redwood City, CA, United States, 94063

Directors & Officers

Name Title Year Born
Dr. Mark A. Goldsmith M.D., Ph.D. CEO, President & Chairman 1962
Mr. Jack Anders Chief Financial Officer 1977
Ms. Margaret A. Horn J.D. Chief Operating Officer 1963
Mr. Jeffrey Cislini J.D. Senior VP, General Counsel & Corporate Secretary 1975
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. President of Research & Development 1961
Dr. Martin D. Burke M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder & Member of Scientific Advisory Board 1981
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder & Member of Scientific Advisory Board NA
Mr. Walter Reiher Ph.D. Chief Information Officer NA
Ms. Jan Smith Ph.D. Chief Scientific Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 15, 2026 Mark A Goldsmith N/A Sale 120.00K $150.09 $18.01M
Mar 17, 2026 Jack Anders N/A Sale 2.75K $99.48 $273.87K
Mar 17, 2026 Lin Wei N/A Sale 2.07K $99.48 $206.22K
Mar 17, 2026 Margaret A Horn N/A Sale 4.58K $99.48 $455.92K
Mar 17, 2026 Mark A Goldsmith N/A Sale 12.87K $99.48 $1.28M
Mar 17, 2026 Stephen Michael Kelsey N/A Sale 4.30K $99.48 $427.96K
Mar 17, 2026 Xiaolin Wang N/A Sale 2.01K $99.48 $199.95K
Mar 02, 2026 Mark A Goldsmith N/A Sale 30.00K $101.22 $3.04M
Mar 02, 2026 Mark A Goldsmith N/A Sale 6.00K $101.30 $607.80K
Jan 07, 2026 Jack Anders N/A Sale 10.00K $98.00 $980.00K
Jan 07, 2026 Margaret A Horn N/A Sale 75.00K $100.56 $7.54M
Dec 16, 2025 Stephen Michael Kelsey N/A Sale 5.45K $76.82 $418.44K
Dec 16, 2025 Mark A Goldsmith N/A Sale 15.39K $76.82 $1.18M
Dec 16, 2025 Margaret A Horn N/A Sale 4.85K $76.82 $372.35K
Dec 16, 2025 Jack Anders N/A Sale 3.10K $77.09 $239.29K
Nov 25, 2025 Mark A Goldsmith N/A Sale 60.00K $75.08 $4.50M
Nov 18, 2025 Mark A Goldsmith N/A Sale 20.00K $70.38 $1.41M
Nov 12, 2025 Mark A Goldsmith N/A Sale 20.00K $65.07 $1.30M
Nov 07, 2025 Mark A Goldsmith N/A Sale 30.00K $60.31 $1.81M
Oct 13, 2025 Stephen Michael Kelsey N/A Sale 25.00K $48.54 $1.21M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 16.72M Dec 31, 2025 7.86% $0.02 6.75%
Farallon Capital Management, L.L.C. 13.60M Mar 31, 2026 6.40% $7.54 -6.71%
BlackRock Inc 11.21M Mar 31, 2026 5.27% $0.02 25.61%
HHG PLC 9.77M Mar 31, 2026 4.59% $0.45 -20.62%
Baker Bros Advisors LP 9.56M Mar 31, 2026 4.49% $5.34 1.06%
FMR Inc 8.46M Mar 31, 2026 3.98% $0.04 -1.44%
Vanguard Capital Management, LLC 8.36M Mar 31, 2026 3.93% $0.02 0.00%
Nextech Invest, Ltd. 7.60M Dec 31, 2025 3.58% $58.53 0.00%
Vanguard Portfolio Management, LLC 7.50M Mar 31, 2026 3.53% $0.04 0.00%
Paradigm Biocapital Advisors LP 6.66M Mar 31, 2026 3.13% $13.23 0.17%
Wellington Management Company LLP 6.03M Mar 31, 2026 2.84% $0.11 -13.74%
Adage Capital Partners Gp LLC 5.48M Mar 31, 2026 2.58% $0.82 148.26%
State Street Corp 4.40M Mar 31, 2026 2.07% $0.01 7.14%
UBS Group AG 4.39M Mar 31, 2026 2.06% $0.06 42.06%
Geode Capital Management, LLC 3.34M Mar 31, 2026 1.57% $0.02 5.57%
Alphabet Inc 3.29M Mar 31, 2026 1.55% $7.97 -1.57%
T. Rowe Price Associates, Inc. 3.23M Mar 31, 2026 1.52% $0.04 -5.07%
Bvf Inc 2.86M Mar 31, 2026 1.34% $8.85 -14.90%
Casdin Capital, LLC 2.58M Mar 31, 2026 1.21% $18.98 0.00%
Woodline Partners LP 2.51M Mar 31, 2026 1.18% $0.92 0.23%

Shares Statistics

Shares Outstanding: 212.60M
Shares Float: 194.17M
% Insiders: 189.50%
% Institutions: 9,559.70%
Short % Float: 5.76%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 6.32M 2.97% ▲ 5.60% Apr 30, 2026
2 Vanguard Small Cap Index 4.57M 2.15% ▲ 5.12% Apr 30, 2026
3 Fidelity Growth Compy Commingled Pl S 3.41M 1.61% ▲ 0.54% Apr 30, 2026
4 Vanguard Health Care Inv 2.58M 1.21% ▲ 8.03% Mar 31, 2026
5 Vanguard Small Cap Growth Index Inv 2.56M 1.21% ▲ 5.34% Apr 30, 2026
6 Fidelity Growth Company Fund 2.54M 1.19% ▲ 0.99% Apr 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 2.22M 1.04% ▲ 9.06% Apr 30, 2026
8 Janus Henderson Mid Cap Growth MA 2.09M 0.98% ▲ 0.00% Sep 30, 2025
9 iShares Biotechnology ETF 1.27M 0.60% ▲ 1.46% May 29, 2026
10 Janus Henderson Global Life Sciences D 1.09M 0.51% ▼ 5.54% Mar 31, 2026

Valuation Metrics

Enterprise Value: $30.96B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $32.71B
EBITDA: $-1.38B
Book Value: $7.49
Earnings/Share: $-7.11
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -37.53%
ROE (TTM): -76.67%
Revenue (TTM): $742.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -95.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 7.14x 0.01x 0.31x -48.80x -0.02x
2024-12-31 14.20x 0.01x 0.11x N/A -0.02x
2023-12-31 13.06x 0.00x 0.11x -1,607.87x -0.02x
2022-12-31 10.65x 0.01x 0.16x -26.75x -0.03x
2021-12-31 9.77x 0.01x 0.18x -15,667.33x -0.03x
2020-12-31 9.63x 0.01x 0.16x -1,559.11x -0.04x
2019-12-31 3.11x 0.00x 0.31x -510.57x 0.00x
2018-12-31 2.80x 0.00x 0.43x -347.66x 0.00x
2017-12-31 1.24x 0.00x 0.70x -302.22x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RVMD.US!